Solvay invites shareholders to the 2021 Annual General Meeting


Brussels, April 9, 2021, 8.30 a.m. CEST - Solvay today announced that it has published materials for the next General Shareholders' Meeting, which will be held on Tuesday May 11, 2021 in Brussels, at 10.30 a.m. CEST. All documents relating to this meeting are now available on 

In view of the exceptional situation related to the coronavirus, the Solvay General Shareholders’ Meeting will take place virtually. The Company has taken all necessary steps to enable shareholder interactions and questions at the meeting and has provided registration and participation information (see below). The company will continue to closely monitor the situation and will inform shareholders in due course, by means of a press release and on the company's website of any developments regarding the Shareholders’ meeting. 

Agenda’s main topics submitted to shareholders’ approval 

Shareholders will be asked to vote on a number of resolutions. They include the approval of the financial statements for the financial year 2020, the compensation report and the discharge to be given to the Directors and the auditors.

The Board will also propose to approve a total gross dividend of €3.75 per share. Solvay continues to execute on its value-enhancing G.R.O.W. strategy to drive consistent, profitable growth and increased earnings power. As the Covid-19 crisis unfolded, the Group quickly adapted priorities to accelerate cost savings and cash delivery, generating a record level of free cash flow and €332 million of cost savings in 2020. Further, Solvay made significant progress towards its One Planet sustainability targets. This performance reflects the decisive nature of the Group’s response and the resilience and sustainability of its operating model. As a result, the Board proposes to distribute a stable dividend compared to 2019. 

Solvay is also nominating, for shareholder approval, two new director nominees, Dr. Wolfgang Colberg and Edouard Janssen, to replace Amparo Moraleda and Evelyn du Monceau, whose mandates come to an end in May 2021. 

Dr. Wolfgang Colberg, who is 61 and of German nationality, is currently Chairman of the Board of ChemicaInvest and Industrial Partner at Deutsche Invest Capital Partners. He is a Board member of Thyssenkrupp, Pernod Ricard and Burelle. Dr. Colberg started his career at the Bosch group, where he held various leadership positions in Europe and Central Asia. He was then Chief Financial Officer at BSH, before being Chief Financial Officer of Evonik Industries AG between 2009 and 2013. He was then an Industrial Partner of CVC Capital Partners between 2013 and 2019. Dr. Wolfgang Colberg holds a PhD in Business administration. Dr. Colberg will serve as independent Director on the Board of Solvay.

Mr. Edouard Janssen, who is 42 and of Belgian nationality, is currently  an Advisory Board member of the INSEAD Hoffmann Institute.  Prior to this, Mr. Janssen spent most of his career within Solvay (until February 2021), holding various leadership positions in Europe and the Americas, including Vice‐President Strategy and M&A Manager, Finance Director of Solvin (a joint-venture between Solvay and BASF active in ChloroVinyls in Europe and in Russia) and Vice‐President & General Manager of the Aroma Global Business Unit for North and Latin Americas. Mr. Janssen holds an MBA at INSEAD.

Nicolas Boël, Chairman of Solvay’s Board of Directors commented: “On behalf of the Board of Directors, I would like to thank Ms. Evelyn du Monceau and Ms. Amparo Moraleda for their significant contributions. We are pleased to propose Dr. Wolfgang Colberg and Mr. Edouard Janssen for appointment, confident that their experiences will further enhance the Board’s effectiveness at the service of Solvay ’s continued future development.” 

Meeting information

The meeting will be broadcast via a live webcast, accessible to all shareholders via the Lumi AGM+ platform. Shareholders are invited to either vote by proxy before the meeting or electronically during the meeting.  

Although the webcast enables live interaction, shareholders are strongly encouraged to submit their questions in writing prior to the meeting, so that answers provided at the meetings can be as comprehensive and accurate as possible. All questions can be addressed to

Visit the Shareholders’ Meeting dedicated page for more details regarding the agenda, the admission conditions and voting methods.


About GlobeNewswire

One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire


Correction: the number of shares indicated – 380.396.585 and declared dividends per share – 0,0198 EUR. On 15 April 2021 AB “Klaipėdos nafta” (hereinafter – Company) received a proposal from the Ministry of Energy of the Republic of Lithuania (hereinafter referred to as the Shareholder), that executes the rights of the Shareholder – the Republic of Lithuania that owns 275 687 444 ordinary registered shares, making 72,45 per cent of the total amount of the Company’s shares, on an alternative draft resolution of the issue on the agenda of the ordinary registered meeting of shareholders of the Company to be convened on 30 April 2021. Following paragraphs 3, 4 and 5 of Article 25 of the Law on Companies of the Republic of Lithuania, the Shareholder as the person exercising the right to propose draft resolutions of the Company’s General Meeting, holding shares that grant at least 1/20 of all the votes, proposes to approve the following draft resolution of the fourth item on the agenda of th

Sampo plc: Disclosure Under Chapter 9 Section 5 of the Securities Market Act (BlackRock, Inc.)16.4.2021 14:30:00 CEST | Press release

SAMPO PLC STOCK EXCHANGE RELEASE 16 April 2021 at 3:30 pm Disclosure Under Chapter 9 Section 5 of the Securities Market Act (BlackRock, Inc.) Sampo plc (business code 0142213-3) has received a disclosure under Chapter 9, Section 5 of the Securities Markets Act, according to which the total number of voting rights attached to Sampo A shares (ISIN: FI009003305) owned directly, indirectly or through financial instruments by BlackRock, Inc. (USA tax ID 32-0174421) and its funds increased on 15 April 2021 above five (5) per cent of Sampo plc’s total voting rights. In addition, the disclosure obligation arose due to the number of Sampo A shares owned directly or indirectly by BlackRock, Inc. and its funds increasing above 5 per cent. Sampo's share capital comprises 555,351,850 shares, of which 554,151,850 are A shares and 1,200,000 are B shares. Each A share entitles its holder to one (1) vote and each B share to five (5) votes. Thus, the total number of votes is 560,151,850. Total positions

CrossAmerica Partners to Announce First Quarter 2021 Earnings Results on May 1016.4.2021 12:45:00 CEST | Press release

Allentown, April 16, 2021 (GLOBE NEWSWIRE) -- CrossAmerica Partners to Announce First Quarter 2021 Earnings Results on May 10 ALLENTOWN, PA, April 16, 2021 – CrossAmerica Partners LP (NYSE: CAPL) today announced that it will release its first quarter 2021 results after the market closes on Monday, May 10, 2021. In conjunction with the news release, management will host a conference call on Tuesday, May 11, at 9:00 a.m. Eastern Time. The conference call numbers are 800-774-6070 or 630-691-2753 and the passcode for both is 7265208#. A live audio webcast of the conference call and the related earnings materials, including reconciliations of any non-GAAP financial measures to GAAP financial measures and any other applicable disclosures, will be available on that same day on the investor section of the CrossAmerica website ( To listen to the audio webcast, go to A

Nexstim Receives Positive Feedback from Mind Matters Psychiatry MD on Use of Their Two NBT® Systems to Treat MDD16.4.2021 11:00:00 CEST | Press release

Press release, Helsinki, 16.04.2021, 12.00 pm (EEST) Nexstim Receives Positive Feedback from Mind Matters Psychiatry MD on Use of Their Two NBT® Systems to Treat MDD Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") announces that the company’s SmartFocus® nTMS technology used at Mind Matters Psychiatry MD, US has generated positive feedback from its use in treating patients with depression. Oladele Adebogun M.D. said, “I was initially introduced to Nexstim by the early outcomes of their registry which showed 50% remission rates in a small number of patients suffering from major depressive disorder. I purchased my first system and have been so impressed with my own patient outcomes that I have added this second system for my patients located in Flower Mound, Texas. I have even been able to successfully treat those patients who failed to respond to TMS on our prior non-Nexstim system. I am proud to contribute to the latest Nexstim treatment outcomes of triple the number of pat


Auction date2021-04-16Loan1062Coupon0.125 %ISIN-codeSE0013935319Maturity2031-05-12Tendered volume, SEK mln750 +/- 400Volume offered, SEK mln4,000Volume bought, SEK mln750Number of bids12Number of accepted bids3Average yield0.367 %Lowest accepted yield0.367 %Highest yield0.368 %% accepted at lowest yield 65.00 Auction date2021-04-16Loan1053Coupon3.50 %ISIN-codeSE0002829192Maturity2039-03-30Tendered volume, SEK mln500 +/- 250Volume offered, SEK mln1,400Volume bought, SEK mln500Number of bids5Number of accepted bids2Average yield0.696 %Lowest accepted yield0.693 %Highest yield0.698 %% accepted at lowest yield 100.00 Auction date2021-04-16LoanREGS Kingdom of SwedenCoupon0.125 %ISIN-codeXS2226974504Maturity2030-09-09Tendered volume, SEK mln250 +/- 250Volume offered, SEK mln600Volume bought, SEK mln250Number of bids6Number of accepted bids3Average yield0.287 %Lowest accepted yield0.281 %Highest yield0.291 %% accepted at lowest yield 50.00

Prostate cancer study to be initiated at Uppsala University Hospital with NanoZolid technology®16.4.2021 09:00:00 CEST | Press release

UPPSALA, SWEDEN – LIDDS AB (publ) announced today that an application for a new clinical study at Uppsala University Hospital has been submitted. The study will assess intratumoral injections of NZ-DTX Depot, containing the cytotoxic agent docetaxel, in men with prostate cancer who are scheduled for prostatectomy. The trial is originated by the principal investigator of the trial, Dr Michael Häggman, Associate Professor at the Department of Surgical Sciences in Urology, Uppsala University Hospital. The study is planned to start in mid of this year and it will enroll 10- 15 patients to be treated with NZ-DTX prior to planned surgery. “The NanoZolid technology is suitable to combine with the MRI/TRUS injection technique for a high precision intratumoral delivery of NZ-DTX Depot. Treating patients prior to removal of the prostate gland will provide exhaustive information with regards to local effects in the tumor and surrounding tissue”, commented Dr Michael Häggman. “We are very pleased

Notice of Annual General Meeting in Eolus Vind AB (publ)16.4.2021 08:30:00 CEST | Press release

Hässleholm, Sweden, April 16th, 2021 The shareholders of Eolus Vind AB (publ) are hereby invited to attend the Annual General Meeting (“AGM”) to be held on May 19, 2021. The Board of Directors has decided that the AGM should be conducted by way of postal vote pursuant to temporary legislation being in effect in 2021. This means that the AGM will be held without the physical presence of shareholders, representatives or third parties. The shareholders will therefore only be able to exercise their voting rights by postal voting in the manner prescribed below. An address in which the CEO Per Witalisson comments on Eolus’ operations and any questions submitted to the company will be published on Eolus’s website on May 19, 2021. Information on the resolutions passed at the AGM will be disclosed on May 19, 2021, when the outcome of the postal voting has been confirmed. Right to attend Shareholders who wish to attend the AGM must be recorded in the share register maintained b